Amerikanische Gesellschaft für Hirudotherapie

Contemporary device management of cardiogenic shock following acute myocardial infarction

Review published in Heart failure reviews (2021)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungSuleiman T et al. · Heart failure reviews, 2021

Abstract

Despite advances in the overall management of acute myocardial infarction (AMI), cardiogenic shock in the setting of AMI (CS-AMI) continues to be associated with poor patient outcomes. There are multiple devices that can be used in CS-AMI to support the failing circulation, although their utility in improving outcomes as compared with conventional pharmacotherapy of vasopressors and inotropes remains to be established. This contemporary review provides an update on the evidence base for each of these techniques. In CS-AMI, acute thrombotic occlusion of a major epicardial artery leads to hypoxia and myocardial ischaemia in the territory subtended by that vessel. The resultant regional dysfunction in myocardial contractility can severely compromise stroke volume and result in acute circulatory failure, systemic hypoperfusion, lactic acidosis, multi-organ failure and ultimately death.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHeart-Assist DevicesHumansIntra-Aortic Balloon PumpingMyocardial InfarctionShock, CardiogenicStroke VolumeTreatment Outcome

Zusammenfassung

Despite advances in the overall management of acute myocardial infarction (AMI), cardiogenic shock in the setting of AMI (CS-AMI) continues to be associated with poor patient outcomes.

Warum dies für die Hirudotherapie relevant ist

This review provides an update on the evidence base for multiple devices used to support the failing circulation in cardiogenic shock complicating acute myocardial infarction (CS-AMI), comparing their utility against conventional pharmacotherapy of vasopressors and inotropes. The abstract describes the pathophysiology of CS-AMI, noting that acute thrombotic occlusion of a major epicardial artery can lead to circulatory failure, systemic hypoperfusion, lactic acidosis, multi-organ failure, and death, and that outcomes remain poor despite advances in management. This review makes no mention of leeches, hirudin, leech therapy, or the leech secretome. Caveat: it has no identifiable relevance to hirudotherapy or ASH's domain.

Zitation

Contemporary device management of cardiogenic shock following acute myocardial infarction

Suleiman T et al. · Heart failure reviews, 2021

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisCardiovascularCardiologyOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.